Procell Therapeutics Inc.
Records under this name other than the patents Procell Therapeutics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
Showing 1 to 5 of 5 · Back to Procell Therapeutics Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,586,544 | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component Formerly held Lapsed on the fee record Ended Nov 19, 2025 · From the USPTO record | Lapsed on the fee record | Ended Nov 19, 2025 | From the USPTO record |
| US 8,470,971 | Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient Lapsed on the fee record Ended Jun 25, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 25, 2025 | From the USPTO record |
| US 8,450,279 | Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same Lapsed on the fee record Ended May 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 28, 2025 | From the USPTO record |
| US 8,445,443 | Cell permeable p18 recombinant proteins, polynucleotides encoding the same, and anticancer composition comprising the same Lapsed on the fee record Ended May 21, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 21, 2025 | From the USPTO record |
| US 8,158,415 | Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells Lapsed on the fee record Ended Apr 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2024 | From the USPTO record |